Health
Indian Company Allowed To Market Biologic Therapy For COVID-19 Patients
India’s Biocon has received approval from the country’s drug regulator to market, Itolizumab injection, to treat cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) in COVID-19 patients, a company statement said.
In 2013, Biocon had launched Itolizumab, an anti-CD6 IgG1 monoclonal antibody biologic therapy for treating chronic plaque psoriasis, which it has now repurposed for treating COVID-19 patients.
Read Also: COVID-19: Nigeria Records 664 New Cases — Total Now 31,987
The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs.
The virus can cause, in the worst scenario, multi-organ failure and even death.
The approval of Itolizumab, from the drug regulator is based on the results from the successful conclusion of a randomised, controlled clinical trial at multiple hospitals in Mumbai and New Delhi, the statement said.
India, ranked third after the United States and Brazil for the number of confirmed COVID-19 cases in the world, has 283,407 active cases with 22,123 deaths reported so far.
Advertise or Publish a Story on EkoHot Blog:
Kindly contact us at [email protected]. Breaking stories should be sent to the above email and substantiated with pictorial evidence.
Citizen journalists will receive a token as data incentive.
Call or Whatsapp: 0803 561 7233, 0703 414 5611
